Navigation Links
Hospira Announces New Contracts With Premier Purchasing Partners for Infusion Devices, Solutions And Equipment
Date:8/21/2008

LAKE FOREST, Ill., Aug. 21 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced new national agreements with Premier Purchasing Partners. The multi-year contracts will provide Premier's 2,000 member hospitals with access to special pricing and terms pre-negotiated by Premier for Hospira's general-purpose medication infusion devices, related sets and disposables, along with intravenous (I.V.) solutions, nutritionals, drug-delivery and gravity administration sets. The five-year Premier agreements will be effective February 1, 2009.

"Premier shares our commitment to improving patient and caregiver safety, while reducing the high costs of healthcare," said Pete Baker, vice president and general manager, Commercial Service Operations, Hospira. "Hospira products and services are well positioned to deliver positive results in these critical areas for the Premier membership. We look forward to collaborating with Premier's member healthcare institutions to provide innovative solutions and drive results."

The new agreements include Hospira's general-purpose medication management technologies, such as the Plum A+(R) and next-generation Symbiq(R) infusion systems with Hospira MedNet(R) safety software; and pain management pumps, such as LifeCare PCA(R) with Hospira MedNet and GemStar(R) ambulatory devices. These products play a critical role in improving patient safety as well as enhancing quality of care and clinician workflow. Also covered within the agreement is access to contracts for Hospira's I.V. solutions and associated equipment portfolio, including the company's environmentally preferable VisIV(R) container. This represents the first opportunity for Hospira to offer these full product lines to Premier member healthcare institutions on contract.

About Premier Inc., 2006 Malcolm Baldrige National Quality Award recipient

Serving more than 2,000 U.S. hospitals and 53,000-plus other healthcare sites, the Premier healthcare alliance and its members are transforming healthcare together. Owned by not-for-profit hospitals, Premier operates one of the leading healthcare purchasing networks and the nation's most comprehensive repository of hospital clinical and financial information. A subsidiary operates one of the nation's largest policy-holder owned, hospital professional liability risk-retention groups. A world leader in helping healthcare providers deliver dramatic improvements in care, Premier is working with the United Kingdom's National Health Service North West and the Centers for Medicare & Medicaid Services to improve hospital performance. Headquartered in San Diego, Premier has offices in Charlotte, N.C., Philadelphia and Washington. For more information, visit http://www.premierinc.com.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hospira Reports Second-Quarter 2008 Results
2. Hospira Hosts Conference Call for Second-Quarter 2008 Earnings
3. Hospira Highlights Strategic Initiatives at Its 2008 Annual Meeting of Shareholders
4. Hospira to Present at the Bank of America 2008 Health Care Conference on May 14
5. Hospira Acquires Sculptor
6. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
7. Hospira to Present at the Bear Stearns 10th Annual London Healthcare Conference on March 13
8. Hospira Reports Fourth-Quarter and Full-Year 2007 Results
9. Hospira Launches Generic Irinotecan Injection
10. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
11. Hospira Hosts Conference Call for Fourth-Quarter 2007 Results and 2008 Projections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join ... This festival offers entertainment for everyone — from the avid gardener to the landscape ... very high quality event held in a grand venue, and we are certainly looking ...
(Date:4/21/2017)... ... April 21, 2017 , ... A new medical study ... replacement patients; post-operative recovery just might be even better than they imagined. Researchers ... osteoarthritis following surgery: 262 patients under 65 and 103 patients over 75. The ...
(Date:4/21/2017)... ... April 21, 2017 , ... National pest management association survey conducted in 2010 ... bug infestations over the 5-year period. In 2015 10% or US$750 million per annum ... bug infested properties. , The health and economic consequences of bed bug ...
(Date:4/21/2017)... ... April 21, 2017 , ... In a recently released ... a summer camp for kids in Dana Point, parents are challenged to find ways ... writers caution parents to find age appropriate activities that both reinforce their child’s learning ...
(Date:4/20/2017)... Carolina (PRWEB) , ... April 20, 2017 , ... ... of the fourth book in its growing library. The Greener The Grass, ... Quarterback and alumnus of Walnut Grove High School, shares a deeply personal, hard-earned ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... , April 19, 2017 Global Prostate ... report on the prostate cancer therapeutics market analyzes ... market. Increasing prevalence of prostate cancer, launch of ... the development of new drugs & therapeutic biological ... drug due to lesser side effects are some ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: